Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of SSS55 Injection in Healthy Subjects in China

NCT07058779 is registered in ClinicalTrials.gov with Shenyang Sunshine Pharmaceutical Co., LTD. as lead sponsor.

NCT NCT07058779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07058779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of SSS55 Injection in Healthy Subjects in China
Lead sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
August 4, 2025
Completion date
December 31, 2027
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety issues